Trodelvy Receives New Indication for Advanced Urothelial Cancer

Web Exclusives - FDA Approvals, Select Drug Profiles

On April 13, 2021, the FDA accelerated the approval of sacituzumab govitecan (Trodelvy; Immunomedics), a Trop-2 antibody and topoisomerase inhibitor, for patients with locally advanced or metastatic urothelial cancer who had received a platinum-containing chemotherapy and either a PD-1 or a PD-L1 inhibitor. The FDA had granted sacituzumab govitecan a breakthrough therapy designation for this indication.

A week earlier, on April 7, 2021, the FDA granted sacituzumab govitecan regular approval for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received ≥2 systemic therapies, at least 1 for metastatic disease. Sacituzumab govitecan was granted an accelerated approval for TNBC in April 2020.

The FDA approval of the new indication for sacituzumab govitecan for the treatment of advanced urothelial cancer was based on results of the TROPHY study, a single-arm, multicenter clinical trial of 112 patients with locally advanced or metastatic urothelial cancer who had received a platinum-containing chemotherapy and either a PD-1 or a PD-L1 inhibitor. Patients received sacituzumab govitecan, 10 mg/kg intravenously, on days 1 and 8 of a 21-day treatment cycle.

The main efficacy measures were the objective response rate (ORR) and the duration of response. The confirmed ORR was 27.7% (95% confidence interval [CI], 19.6-36.9), including 5.4% complete responses and 22.3% partial responses. The median duration of response was 7.2 months (95% CI, 4.7-8.6).

The most common (>25%) adverse reactions reported with sacituzumab govitecan were neutropenia, nausea, diarrhea, fatigue, alopecia, anemia, vomiting, constipation, decreased appetite, rash, and abdominal pain.

Continued approval of this indication may be contingent on the demonstration of a clinical benefit in a confirmatory clinical trial.

Related Items
Lynparza FDA Approved, in Combination With Abiraterone and Prednisone (or Prednisolone), for Metastatic Castration-Resistant Prostate Cancer With BRCA Mutation
June 2023 Vol 16, No 1 published on June 2, 2023 in FDA Approvals
Epkinly FDA Approved for Relapsed or Refractory Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma
June 2023 Vol 16, No 1 published on June 2, 2023 in FDA Approvals
Polivy Receives New Indication for First-Line Treatment of Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, and High-Grade B-Cell Lymphoma
June 2023 Vol 16, No 1 published on June 2, 2023 in FDA Approvals
Nubeqa Now Indicated for Metastatic Hormone-Sensitive Prostate Cancer
Web Exclusives published on December 14, 2022 in FDA Approvals
Imfinzi Receives New FDA Indication for Advanced or Metastatic Biliary Tract Cancer
Web Exclusives published on December 7, 2022 in FDA Approvals
Last modified: August 30, 2021
© Amplity Health. All rights reserved.